Anavex Life Sciences Corp. (Anavex) is a development-stage company. The Company is focused on developing and marketing drug targets for the treatment of cancer and diseases of the central nervous system (CNS). The Company was formerly engaged in the business of providing online photofinishing services through its Website. As of September 30, 2008, the Company had several compounds at various pre-clinical stages. The Company’s portfolio involves new sigma receptor compounds (ligands) in pre-clinical stage that target diseases of the CNS and cancer. Anavex SIGMACEPTOR-N program involves the discovery and development of original drug candidates, targeting neurological and neurodegenerative diseases, such as Alzheimer’s disease, epilepsy and depression. Anavex SIGMACEPTOR-C program involves the discovery and development of original drug candidates targeting cancer.